Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
- Dec 5, 2019Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative ScienceTwo exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research
Dec 2, 2019Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingEmerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation
Dec 2, 2019Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer- Companies to Initiate Phase 3 Trial to Support Global Registrations -
Nov 25, 2019Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer
Oct 31, 2019New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)- Results were published online and in the October 31 print edition of the Journal -